CytomX Taps Ex-Alder Bio Exec Campoy as Chief Financial Officer

CytomX Therapeutics has appointed Carlos Campoy to serve as its chief financial officer, the same position he held most recently at Alder BioPharmaceuticals, which was acquired by Lundbeck last year. Campoy’s experience also includes positions at Allergan (NYSE: [[ticker:AGN]]) and Eli Lilly (NYSE: [[ticker:LLY]]). South San Francisco-based CytomX develops antibody cancer drugs. This week, the company began a research partnership with Astellas Pharma that will pay $80 million up front to develop cancer immunotherapies based on CytomX’s proprietary technology.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.